Annual report pursuant to Section 13 and 15(d)

Discontinuing Operations - Summarized results of disposal (Details)

v3.21.1
Discontinuing Operations - Summarized results of disposal (Details) - USD ($)
$ in Thousands
12 Months Ended
Jul. 15, 2019
Jul. 08, 2019
Dec. 31, 2020
Dec. 31, 2019
Oct. 24, 2019
Net assets sold:          
Gain (loss) on disposal of business       $ 8,370  
BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Net sales price         $ 153
Discontinuing Operations          
Net assets sold:          
Accounts receivable     $ 0 71  
Discontinuing Operations | BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash received at closing $ 2,258        
Net sales price 19,099        
Net assets sold:          
Accounts receivable 4,271        
Other current assets 1,142        
Fixed assets 2,998        
Operating lease right-of-use assets 1,969        
Patents and other intangible assets 42        
Goodwill 10,106        
Accounts payable and accrued expenses (4,970)        
Obligations under operating leases (2,110)        
Obligations under finance leases (451)        
Deferred revenue (1,046)        
Net assets sold 11,951        
Gain (loss) on disposal of business 7,148   0 7,148  
Discontinuing Operations | Clinical Business Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Cash received at closing   $ 747      
Net sales price   2,123      
Net assets sold:          
Goodwill   1,188      
Accounts payable and accrued expenses   (287)      
Net assets sold   901      
Gain (loss) on disposal of business   1,222 $ 0 $ 1,222  
Excess Consideration Note | Discontinuing Operations | BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncash amount received at closing 6,795        
Repayment of ABL and accrued interest | Discontinuing Operations | BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncash amount received at closing 2,906        
Repayment of Term Note and accrued interest | Discontinuing Operations | BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncash amount received at closing 6,250        
Repayment of certain accounts payable and accrued expenses | Discontinuing Operations | BioPharma Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncash amount received at closing $ 890        
Advance from siParadigm received in cash | Discontinuing Operations | Clinical Business Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Advance from siParadigm received in cash   (1,000)      
Earn-Out from siParadigm | Discontinuing Operations | Clinical Business Disposal          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Noncash amount received at closing   $ 2,376